SCHEMBL24539766

SCHEMBL24539766

CC(C)CCCNC(=O)OC1CCC1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 2/20 0.51
GAA P10253 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.40
RAB9A P51151 1/20 0.40
BRD4 O60885 4/20 0.39
TPSAB1 Q15661 3/20 0.39
TPSD1 Q9BZJ3 3/20 0.39
TPSG1 Q9NRR2 3/20 0.39
NR1H4 Q96RI1 3/20 0.39
BCHE P06276 1/20 0.38
HRH3 Q9Y5N1 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
HDAC4 P56524 1/20 0.36
HDAC1 Q13547 1/20 0.36
MMP2 P08253 1/20 0.35
MMP8 P22894 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16363611 0.92 EPHX1 (0.54) EPHX1GAASMN1; SMN2RAB9ABRD4
SCHEMBL24539765 0.90 EPHX1 (0.54) EPHX1GAASMN1; SMN2RAB9ATPSAB1
SCHEMBL8243750 0.81 GAA (0.63) EPHX1GAABCHE
SCHEMBL22134987 0.80 EPHX1 (0.44) EPHX1GAASMN1; SMN2RAB9A
SCHEMBL21786685 0.79 EPHX1 (0.46) EPHX1GAASMN1; SMN2RAB9ANR1H4
SCHEMBL22134964 0.78 EPHX1 (0.66) EPHX1GAABCHE
SCHEMBL10879403 0.78 EPHX1 (0.65) EPHX1GAATPSAB1TPSD1TPSG1
SCHEMBL20928290 0.78 EPHX1 (0.65) EPHX1GAABCHEMEN1KMT2A
SCHEMBL22136179 0.77 EPHX1 (0.69) EPHX1GAABCHE
SCHEMBL16374741 0.77 EPHX1 (0.64) EPHX1GAABCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240238430-A1 ANTI-CEA IMMUNOCONJUGATES, AND USES THEREOF BOLT BIOTHERAPEUTICS, INC. (US) 2024-07-18 US disclosed
US-20240238430-A1 ANTI-CEA IMMUNOCONJUGATES, AND USES THEREOF BOLT BIOTHERAPEUTICS, INC. (US) 2024-07-18 US disclosed
US-20220195066-A1 ANTI-CEA IMMUNOCONJUGATES, AND USES THEREOF BOLT BIOTHERAPEUTICS, INC. (US) 2022-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240238430-A1 ANTI-CEA IMMUNOCONJUGATES, AND USES THEREOF CA14, CA12, CA13 EPHX1 689/4885GAA 253/4885SMN1; SMN2 4719/4885
US-20220195066-A1 ANTI-CEA IMMUNOCONJUGATES, AND USES THEREOF EPHX2, FAAH2, CYP8B1 EPHX1 5/4885GAA 1173/4885SMN1; SMN2 4786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.